Merck announced recentlythat its new HIV drug Pedro (doravirin tablets) has been officially approved
더 읽어보세요 2020-12-08뉴스 목록
Merck's new HIV drug Pedro (Doravirin) was approved in China
FDA Grants Priority Review and EMA Accepts Regulatory Submission for Pfizer’s Abrocitinib, an Oral Once-Daily JAK1 Inhibitor, for Patients 12 and Up with Moderate to Severe Atopic Dermatitis
Pfizer announced that the U.S. Food and Drug Administration (FDA) accepted for filing and granted Pr
더 읽어보세요 2020-11-02
ViiV Healthcare receives positive CHMP opinion for long-acting regimen for the treatment of HIV
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shion
더 읽어보세요 2020-10-18
European Commission Grants Marketing Authorization for Jyseleca® ▼ (Filgotinib) for the Treatment of Adults With Moderate to Severe Active Rheumatoid Arthritis
Gilead Sciences and Galapagos NV today announced that the European Commission (EC) has granted marke
더 읽어보세요 2020-09-27
Janssen Announces European Commission Decision for Expanded Use of IMBRUVICA® (ibrutinib) in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukaemia (CLL)
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Comm
더 읽어보세요 2020-09-09
PIQRAY® is approved and now available in Canada as the first and only treatment specifically for patients with a PIK3CA mutation in HR-positive, HER2-negative advanced breast cancer
Approval is based on results from SOLAR-1, where PIQRAY®in combination with fulvestrant nearly doubl
더 읽어보세요 2020-08-20
Gastrointestinal stromal tumor (GIST) targeted new drugs! Avapritinib will be approved in the EU in September
Blueprint Medicines announced that the European Medicines Agency (EMA) Committee for Medicinal Produ
더 읽어보세요 2020-07-29
Gilead's Veklury has been approved：Veklury is the First Approved Treatment Option for COVID-19 in the European Union
At present,The COVID-19 epidemic continues to spread rapidly around the world. As of 01am, July 04,
더 읽어보세요 2020-07-05
Announcement on the extension of CPHI North America 2020 in September
Dear Customers,Unfortunately, we have to cancel the plan for our participation in the CPHI North Ame
더 읽어보세요 2020-06-18
New medicine for insomnia! Eisai double-acting orexin receptor antagonist Dayvigo (lemborexant) is launched in the US!
Japanese pharmaceutical company Eisai recently announced the launch of Dayvigo (lemborexant), a new
더 읽어보세요 2020-06-16